Literature DB >> 7286578

Normal metabolism of morphine in cirrhosis.

R V Patwardhan, R F Johnson, A Hoyumpa, J J Sheehan, P V Desmond, G R Wilkinson, R A Branch, S Schenker.   

Abstract

Morphine disposition and elimination was studied in 6 healthy male subject s and 6 male patients with cirrhosis, to assess the role of differences, if any, on the reported intolerance of morphine in cirrhosis. In addition the elimination of indocyanine green was studied in the same subjects on a separate occasion. The elimination half-life of indocyanine green was increased and its plasma clearance was markedly reduced in patients with cirrhosis as compared with controls (p less than 0.05). In contrast the disposition and elimination of morphine were unaffected by moderate to severe cirrhosis. Furthermore, while marked sedation was observed in normal subjects, the cirrhotics demonstrated mild sedation with no clinical evidence of hepatic coma. The normal elimination of morphine in cirrhosis is in contrast to the decreased elimination of high clearance drugs metabolized by oxidation, such as lidocaine and meperidine. Morphine is also normally a high clearance drug that is detoxified by conjugation with glucuronic acid. Since intra- or extrahepatic shunting, or both, in cirrhosis do not significantly impair morphine clearance, we postulate that significant extrahepatic morphine conjugation may occur in both normal subjects and in patients with cirrhosis. Furthermore, the reported morphine intolerance to the central effects of morphine cannot be explained by impaired drug elimination and increased availability of morphine to cerebral receptors.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7286578

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  37 in total

1.  Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis.

Authors:  J I Macdonald; S M Wallace; V Mahachai; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Advances in understanding alcohol withdrawal states.

Authors:  F J Lichtigfeld; M A Gillman
Journal:  Postgrad Med J       Date:  1991-07       Impact factor: 2.401

Review 3.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 4.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

5.  Absence of morphine glucuronidation in the human lung.

Authors:  F M Ratcliffe
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 6.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

7.  The metabolism and bioavailability of morphine in patients with severe liver cirrhosis.

Authors:  J Hasselström; S Eriksson; A Persson; A Rane; J O Svensson; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

Review 8.  [Opioids during anesthesia in liver and renal failure].

Authors:  C Höhne; B Donaubauer; U Kaisers
Journal:  Anaesthesist       Date:  2004-03       Impact factor: 1.041

9.  Treatment of liver disease with malotilate. A pharmacokinetic and pharmacodynamic phase II study in cirrhosis.

Authors:  M Bührer; J Y Le Cotonnec; M Wermeille; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 10.  Extrahepatic metabolism of drugs in humans.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.